Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$1.20
-4.4%		$1.38
$1.00
▼
$2.23
$14.08M1.66459,160 shs405,488 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$0.44
+1.6%		$4.25
$0.39
▼
$19.11
$37.68M1.673.46 million shs9.76 million shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$8.46
-0.4%		$7.92
$3.95
▼
$9.40
$38.49M1.533,536 shs3,949 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
+0.40%-8.76%-31.69%+12.61%-34.21%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+6.12%-85.71%-89.30%-96.55%-96.36%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
+1.80%+4.17%+6.13%+37.16%+107.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$1.20
-4.4%		$1.38
$1.00
▼
$2.23
$14.08M1.66459,160 shs405,488 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$0.44
+1.6%		$4.25
$0.39
▼
$19.11
$37.68M1.673.46 million shs9.76 million shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$8.46
-0.4%		$7.92
$3.95
▼
$9.40
$38.49M1.533,536 shs3,949 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
+0.40%-8.76%-31.69%+12.61%-34.21%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+6.12%-85.71%-89.30%-96.55%-96.36%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
+1.80%+4.17%+6.13%+37.16%+107.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.00
Hold$6.00397.93% Upside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.00
Hold$21.855,041.18% Upside
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.00
Hold$6.75-19.99% Downside

Current Analyst Ratings Breakdown

Latest EYPT, HBIO, and BNGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/20/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Laidlaw logo
Laidlaw
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy ➝ Hold
10/20/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetSector Perform$1.00
10/20/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral
10/20/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral ➝ Underweight
10/20/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform ➝ Neutral$0.50
10/19/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Neutral
10/19/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$1.00
9/2/2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E) ➝ Sell (E+)
9/2/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$20.00 ➝ $4.00
9/1/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/18/2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (E+) ➝ Sell (E)
(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$28.51M0.50N/AN/A$4.37 per share0.28
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$2.79M13.14N/AN/A$3.70 per share0.11
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$87.81M0.44$11.88 per share0.71$3.07 per share2.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$26.40M-$3.02N/AN/AN/A-106.58%-78.78%-48.54%10/29/2026 (Estimated)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$231.96M-$3.74N/AN/AN/A-10,994.73%-135.81%-108.35%11/4/2026 (Estimated)
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$56.70M-$2.31N/AN/AN/A-11.86%-33.13%-4.80%11/10/2026 (Estimated)

Latest EYPT, HBIO, and BNGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$0.45N/AN/AN/A$8.44 millionN/A
11/10/2026Q3 2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$0.17N/AN/AN/A$21.80 millionN/A
11/4/2026Q3 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.8945N/AN/AN/A$0.23 millionN/A
8/11/2026Q2 2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$0.21-$0.14+$0.07-$0.64$21.45 million$22.73 million
8/10/2026Q2 2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$0.67-$0.64+$0.03-$0.64$7.55 million($6.67) million
8/5/2026Q2 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$1.01-$1.09-$0.08-$0.2720$0.45 million$0.51 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.11
2.48
1.96
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
4.50
4.46
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
4.94
1.87
0.98

Institutional Ownership

CompanyInstitutional Ownership
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
11.35%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%

Insider Ownership

CompanyInsider Ownership
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.65%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
5.13%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
17.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
9711.78 million11.70 millionNo Data
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
21486.21 million81.79 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3394.55 million3.78 millionNo Data

Recent News About These Companies

Harvard Bioscience forms scientific advisory board with four members
October 6, 2026  |  streetinsider.comhttps://www.streetinsider.com/Board+Changes/Harvard+Bioscience+forms+scientific+advisory+board+with+four+members/27155440.html
Harvard Bioscience Announces Creation of Scientific Advisory Board
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375994/11635/en/harvard-bioscience-announces-creation-of-scientific-advisory-board.html
Harvard Bioscience stock trades steady as investors look to latest revenue trends
August 31, 2026  |  ad-hoc-news.deA
Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/harvard-bioscience-hbio-q2-2026-134257907.html
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/harvard-bioscience-inc-hbio-q2-190132956.html
Harvard Bioscience Announces Second Quarter 2026 Financial Results
August 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/harvard-bioscience-announces-second-quarter-2026-financial-results-1036440452
Harvard Bioscience, Inc. (HBIO) Q2 FY2026 earnings call transcript
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/HBIO/earnings/HBIO-Q2-2026-earnings_call-666504.html
Harvard Bioscience targets 3% to 5% full-year 2026 revenue growth as CMT and China mix shifts gross margin to 57% to 59%
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4630935-harvard-bioscience-targets-3-percent-to-5-percent-full-year-2026-revenue-growth-as-cmt-and
Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance
August 12, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/harvard-bioscience-beats-q2-estimates-and-raises-2026-revenue-guidance/ar-AA29QXZF
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934836-harvard-bioscience-inc-hbio-q2-2026-earnings-call-transcript
Harvard Bioscience Advances Transformation with Project Viking Launch
August 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/harvard-bioscience-advances-transformation-with-project-viking-launch?utm_source=marketbeat.com&utm_medium=referral
Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million
August 11, 2026  |  quiverquant.comQ
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334135/11635/en/harvard-bioscience-schedules-second-quarter-2026-earnings-conference-call-for-august-11-2026-at-8-00-am-et.html
HBIO Share News Today
July 7, 2026  |  uk.investing.comhttps://uk.investing.com/equities/harvard-bioscienc-news/8
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors
June 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/harvard-bioscience-shareholders-expand-equity-plans-elect-directors?utm_source=marketbeat.com&utm_medium=referral
Harvard Bioscience Balances Margin Gains With Soft Sales
May 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/harvard-bioscience-balances-margin-gains-with-soft-sales?utm_source=marketbeat.com&utm_medium=referral
HBIO Q1 2026 Earnings Transcript
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/hbio-q1-2026-earnings-transcript-163703654.html
Harvard Bioscience: Q1 Earnings Snapshot
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/harvard-bioscience-q1-earnings-snapshot-114025064.html
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript
May 13, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/harvard-bioscience-inc-nasdaqhbio-q1-2026-earnings-call-transcript-1761091/
Harvard Bioscience, Inc.: Harvard Bioscience Announces First Quarter 2026 Financial Results
May 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68469469-harvard-bioscience-inc-harvard-bioscience-announces-first-quarter-2026-financial-results-399.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bionano Genomics stock logo

Bionano Genomics NASDAQ:BNGO

$1.20 -0.06 (-4.40%)
Closing price 03:59 PM Eastern
Extended Trading
$1.18 -0.02 (-1.26%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$0.44 +0.01 (+1.63%)
Closing price 03:59 PM Eastern
Extended Trading
$0.43 -0.01 (-2.29%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$8.46 -0.04 (-0.41%)
Closing price 03:58 PM Eastern
Extended Trading
$8.40 -0.05 (-0.59%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas